U.S. District Judge Edward Chen of the Northern District of California (Photo: Jason Doiy/ALM)
A putative class of HIV drug consumers has mostly cleared its first hurdle in an antitrust battle with Gilead Sciences Inc. U.S. District Judge Edward Chen dismissed plaintiffs’ claims of a wide-ranging antitrust conspiracy between Gilead and several other pharma companies—albeit with leave to amend. But Chen also ruled that the plaintiffs had adequately pleaded multiple Sherman Act and state antitrust claims against Gilead only.
